-
1
-
-
49849099533
-
DU-176b, a potent and orally active factor Xa inhibitor: In vitro and in vivo pharmacological profiles
-
Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6(9):1542-9.
-
(2008)
J Thromb Haemost
, vol.6
, Issue.9
, pp. 1542-1549
-
-
Furugohri, T.1
Isobe, K.2
Honda, Y.3
Kamisato-Matsumoto, C.4
Sugiyama, N.5
Nagahara, T.6
-
2
-
-
84971609136
-
-
Daiichi Sankyo Company, Ltd
-
Lixiana (edoxaban tosilate hydrate tablets): full prescribing information. Tokyo: Daiichi Sankyo Company, Ltd.; 2014.
-
(2014)
Full Prescribing Information. Tokyo
-
-
-
3
-
-
80053580161
-
-
Parsippany: Daiichi Sankyo Inc
-
SavaysaTM (edoxaban) tablets for oral use: full prescribing information. Parsippany: Daiichi Sankyo Inc.; 2015.
-
(2015)
Full Prescribing Information
-
-
-
4
-
-
77953787643
-
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor
-
Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitoredoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743-53.
-
(2010)
J Clin Pharmacol
, vol.50
, Issue.7
, pp. 743-753
-
-
Ogata, K.1
Mendell-Harary, J.2
Tachibana, M.3
Masumoto, H.4
Oguma, T.5
Kojima, M.6
-
5
-
-
84869109465
-
Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans
-
Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40(12):2250-5.
-
(2012)
Drug Metab Dispos
, vol.40
, Issue.12
, pp. 2250-2255
-
-
Bathala, M.S.1
Masumoto, H.2
Oguma, T.3
He, L.4
Lowrie, C.5
Mendell, J.6
-
6
-
-
84896111564
-
Edoxaban transport via P-glycoprotein is a key factor for the drug’s disposition
-
Mikkaichi T, Yoshigae Y, Masumoto H, Imaoka T, Rozehnal V, Fischer T, et al. Edoxaban transport via P-glycoprotein is a key factor for the drug’s disposition. Drug Metab Dispos. 2014;42(4):520-8.
-
(2014)
Drug Metab Dispos
, vol.42
, Issue.4
, pp. 520-528
-
-
Mikkaichi, T.1
Yoshigae, Y.2
Masumoto, H.3
Imaoka, T.4
Rozehnal, V.5
Fischer, T.6
-
7
-
-
84885129987
-
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor
-
Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13(5):331-42.
-
(2013)
Am J Cardiovasc Drugs
, vol.13
, Issue.5
, pp. 331-342
-
-
Mendell, J.1
Zahir, H.2
Matsushima, N.3
Noveck, R.4
Lee, F.5
Chen, S.6
-
8
-
-
84983074820
-
-
Rockville: US Food and Drug Administration
-
Center for Drug Evaluation and Research. Guidance for industry-safety testing of drug metabolites. Rockville: US Food and Drug Administration; 2012. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
-
(2012)
Guidance for Industry-Safety Testing of Drug Metabolites
-
-
-
9
-
-
0029916534
-
P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans
-
Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci. 1996;93(9):4001-5.
-
(1996)
Proc Natl Acad Sci
, vol.93
, Issue.9
, pp. 4001-4005
-
-
Schuetz, E.G.1
Schinkel, A.H.2
Relling, M.V.3
Schuetz, J.D.4
-
10
-
-
0032754284
-
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
-
Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999;104(2):147-53.
-
(1999)
J Clin Invest
, vol.104
, Issue.2
, pp. 147-153
-
-
Greiner, B.1
Eichelbaum, M.2
Fritz, P.3
Kreichgauer, H.P.4
Von Richter, O.5
Zundler, J.6
-
11
-
-
0036293982
-
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver
-
Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002;36(1):164-72.
-
(2002)
Hepatology
, vol.36
, Issue.1
, pp. 164-172
-
-
Vavricka, S.R.1
Van Montfoort, J.2
Ha, H.R.3
Meier, P.J.4
Fattinger, K.5
-
12
-
-
84888362796
-
Edoxaban versus warfarin in patients with atrial fibrillation
-
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104.
-
(2013)
N Engl J Med
, vol.369
, Issue.22
, pp. 2093-2104
-
-
Giugliano, R.P.1
Ruff, C.T.2
Braunwald, E.3
Murphy, S.A.4
Wiviott, S.D.5
Halperin, J.L.6
-
13
-
-
84885618705
-
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism
-
Investigators Hokusai VTE, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-15.
-
(2013)
N Engl J Med
, vol.369
, Issue.15
, pp. 1406-1415
-
-
Investigators Hokusai, V.1
Buller, H.R.2
Decousus, H.3
Grosso, M.A.4
Mercuri, M.5
Middeldorp, S.6
-
14
-
-
84983026166
-
-
Sanofi-Aventis, US, LLC
-
Rifadin rifampin capsules USP: package insert. Bridgewater: Sanofi-Aventis, US, LLC; 2013. Available at http://products.sanofi.us/rifadin/Rifadin.pdf.
-
(2013)
Package Insert. Bridgewater
-
-
-
15
-
-
0030911953
-
Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate
-
Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther. 1997;61(5):544-53.
-
(1997)
Clin Pharmacol Ther
, vol.61
, Issue.5
, pp. 544-553
-
-
Borin, M.T.1
Chambers, J.H.2
Carel, B.J.3
Gagnon, S.4
Freimuth, W.W.5
-
16
-
-
84862107719
-
Transcription factor-mediated regulation of carboxylesterase enzymes in livers of mice
-
Zhang Y, Cheng X, Aleksunes L, Klaassen CD. Transcription factor-mediated regulation of carboxylesterase enzymes in livers of mice. Drug Metab Dispos. 2012;40(6):1191-7.
-
(2012)
Drug Metab Dispos
, vol.40
, Issue.6
, pp. 1191-1197
-
-
Zhang, Y.1
Cheng, X.2
Aleksunes, L.3
Klaassen, C.D.4
-
17
-
-
33644843888
-
Roles of rifampicin in drug-drug interactions: Underlying molecular mechanisms involving the nuclear pregnane X receptor
-
Chen J, Raymond K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob. 2006;5:3
-
(2006)
Ann Clin Microbiol Antimicrob
, vol.5
-
-
Chen, J.1
Raymond, K.2
-
18
-
-
33751160865
-
Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism
-
Lam JL, Shugarts SB, Okochi H, Benet LZ. Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J Pharmacol Exp Ther. 2006;319(2):864-70
-
(2006)
J Pharmacol Exp Ther
, vol.319
, Issue.2
, pp. 864-870
-
-
Lam, J.L.1
Shugarts, S.B.2
Okochi, H.3
Benet, L.Z.4
|